Comment: The central justification for aspirin use in primary prevention has long relied on the “Legacy Effect”—the theory that years of early exposure act as a biological investment, paying dividends in reduced cancer risk decades later. This follow-up to the ASPREE trial effectively demolishes that hypothesis for older adults. We are witnessing a stark collision […]
Comment: This study provides the critical ‘why’ behind the findings from this same groups earlier study. In that article, we highlighted that exogenous thyroid hormone is associated with significantly shortened survival in SR+ breast cancer patients. Now, this research explains elucidates the underlying mechanism: thyroid hormone essentially ‘hijacks’ the estrogen receptor, driving proliferation and rendering […]
Comment: Yet another study challenging the safety profile of synthetic T4. The data here is sobering: thyroid cancer survivors on high-dose levothyroxine faced significantly higher risks of developing a second unrelated (not recurrence) cancer, particularly in the GI tract. With hazard ratios for pancreatic, liver cancers reaching nearly 2.5 and 2.0 respectively, this is a […]
Comment: This paper serves as a major wake-up call regarding the risks of thyroid replacement in SR+ breast cancer, which compromises about 80% of cases. The mechanistic finding—that thyroid hormone can reverse Tamoxifen’s action from antagonist to agonist—is a critical piece of the puzzle explaining treatment failure. Furthermore, the observation that Aromatase Inhibitors also showed […]
Comment: While the headline of this study suggests a clear danger, the methodology reveals significant issues which makes the results difficult to trust. They ‘lump’ biologically distinct agents—grouping trace minerals like selenium with high-dose Vitamin C—which renders the ‘antioxidant’ variable clinically meaningless. This is the same mistake done in this trial, which is really a […]
Comment: This study is not the only one showing NSAIDs (vs tylenol) for pain management around surgery has a potential upside. However what this ones suggests is that ketorolac specifically may be a better option than other NSAIDS. that a standard perioperative analgesic acts as a potent anti-cancer agent by ‘abrogating’ the specific inflammatory signal […]
Comment: This is a weak study in numerous ways, with large heterogenicity and a significant results borne of several non-significant studies which always makes it suspect. And if a patient has no contraindications, choosing an NSAID over acetaminophen if pain control is needed seems like the clear winner. The Wonk Debate – Audio Critique & […]
Comment: While the mechanism of repurposing ivermectin is mechanistically sound, we must be careful not to conflate “safe for occasional parasitic use” with “safe for chronic oncologic use.” The authors rely on a safety profile established at low, intermittent doses (150–200 mcg/kg). However, achieving the antitumor concentrations cited here likely requires sustained dosing up to […]
Comment: This is an important pre-clinical study, adding another piece to the connection between levothyroxine and cancer. The finding that T4 promotes tumor growth not by direct cell stimulation, but by driving neoangiogenesis via the integrin αvβ3 receptor, is a critical piece of biologic plausibility. Of course, the major caveat is that this is a […]
Comment: This is a fascinating review of a complex topic. The key clinical pearl here is the paradoxical finding that treatment-induced hypothyroidism (from TKIs/ICPis) often correlates with a favorable prognosis. It underscores the need to closely monitor thyroid function in these patients—not just as a side effect to be managed, but as a potential prognostic […]
